Results 131 to 140 of about 2,162,697 (423)

Poor survival outcomes in HER2 positive breast cancer patients with low grade, node negative tumours [PDF]

, 2009
We present a retrospective analysis on a cohort of low-grade, node-negative patients showing that human epidermal growth factor receptor 2 (HER2) status significantly affects the survival in this otherwise very good prognostic group.
A Ranganathan, BB Rasmussen, D Slamon, DJ Slamon, E A Mallon, EH Romond, H Joensuu, I Smith, J Bartlett, J C Doughty, J Edwards, J Richner, M Schmidt, M Untch, MF Press, N Harbeck, N Quenel, O-P Kallioniemi, PP Rosen, R Rakkhit, S Brown, S Chia, S M Tovey, S Paik, S Paik, S-S Ko, T G Cooke   +26 more
core   +2 more sources

Interplay of integrins and selectins in metastasis

Molecular Oncology, EarlyView.
Here we review the role of integrins and their interplay with selectins in metastasis. The efficacy of integrin‐targeted therapies may be reduced in tumors where metastasis relies heavily on selectins. In certain tumors, integrins and selectins exhibit a synergistic interaction during intraperitoneal dissemination.
Diana Maltseva, Ashot Nersisyan, Alexander Tonevitsky   +2 more
wiley   +1 more source

HER2 Overexpression in Borderline and Malignant Ovarian Tumors: A Cross-sectional Study in an Iranian Population and Literature Review

Middle East Journal of Cancer, 2018
Background: Different studies have investigated the overexpression of human epidermal growth factor receptor 2 in ovarian cancers, in addition to the association between the level of its overexpression and tumor characteristics (tumor grade, subtype ...
Elham Asadinejad, Afshin Abdirad, Fatemeh Nili, Vahid Soleimani   +3 more
doaj  

Epidermal Growth Factor Receptor Pathway [PDF]

Journal of Thoracic Oncology, 2010
The epidermal growth factor receptor (EGFR) pathway has provided a new therapeutic target in non-small cell lung cancer (NSCLC). Two EGFR tyrosine kinase inhibitors (TKIs) are being used globally as systemic treatment in advanced NSCLC. In addition, clinical observations with EGFR TKIS led to the discovery of EGFR activating mutations, which has ...
openaire   +3 more sources

MET and NF2 alterations confer primary and early resistance to first‐line alectinib treatment in ALK‐positive non‐small‐cell lung cancer

Molecular Oncology, EarlyView.
Alectinib resistance in ALK+ NSCLC depends on treatment sequence and EML4‐ALK variants. Variant 1 exhibited off‐target resistance after first‐line treatment, while variant 3 and later lines favored on‐target mutations. Early resistance involved off‐target alterations, like MET and NF2, while on‐target mutations emerged with prolonged therapy.
Jie Hu, Ning Ding, Xiaobo Xu, Yedan Chen, Yong Zhang, Jingwen Liu, Jiebai Zhou, Hairong Bao, Donghui Zhang, Yijun Song, Yang Shao, Yuanlin Song   +11 more
wiley   +1 more source

Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease.

Journal of Clinical Oncology, 2013
PURPOSE EGFR-mutant lung cancer was first described as a new clinical entity in 2004. Here, we present an update on new controversies and conclusions regarding the disease.
K. Ohashi, Y. Maruvka, F. Michor, W. Pao
semanticscholar   +1 more source

Optimal experimental design in an EGFR signaling and down-regulation model [PDF]

arXiv, 2006
We apply the methods of optimal experimental design to a differential equation model for epidermal growth factor receptor (EGFR) signaling, trafficking, and down-regulation. The model incorporates the role of a recently discovered protein complex made up of the E3 ubiquitin ligase, Cbl, the guanine exchange factor (GEF), Cool-1 (Beta-Pix), and the Rho ...
arxiv  

The Molecular Perspective: Epidermal Growth Factor [PDF]

The Oncologist, 2003
Abstract Learning Objectives After completing this course, the reader will be able to: Describe the structure and function of epidermal growth factor and its role in cancer development and treatment.
openaire   +4 more sources

The effects of growth factors on multicellular spheroids formed by chick embryonic retinal cells [PDF]

, 1997
Retinal cells from chick embryos aged 7.5 days of gestation were cultured for two months in a non-adherent suspension culture dish to study the effects of growth factors and co-culture with retinal pigment epithelial cells on their differentiation ...
Matsuo, Nobuhiko, Matsuo, Toshihiko, Takabatake, Mayumi   +2 more
core   +1 more source

Targeted protein degradation in oncology: novel therapeutic opportunity for solid tumours?

Molecular Oncology, EarlyView.
Current anticancer therapies are limited by the occurrence of resistance and undruggability of most proteins. Targeted protein degraders are novel, promising agents that trigger the selective degradation of previously undruggable proteins through the recruitment of the ubiquitin–proteasome machinery. Their mechanism of action raises exciting challenges,
Noé Herbel, Sophie Postel‐Vinay
wiley   +1 more source